Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Anti-interleukin-5 antibody therapy in asthma and allerges

Anti-interleukin-5 antibody therapy in asthma and allerges Jonathan Corren Allergy Medical Clinic, Los Angeles, California, USA Purpose of review Interleukin 5 (IL-5) has been shown to play an instrumental role in eosinophilic Correspondence to Jonathan Corren, MD, Allergy Medical Clinic, 10780 Santa Monica Boulevard, inflammation in allergic diseases. The purpose of this review is to explore clinical trials of Suite 280, Los Angeles, CA 90025, USA anti-IL-5 antibody therapy that have been conducted in patients with asthma, Tel: +1 310 312 5050; e-mail: jcorren@ucla.edu hypereosinophilic syndromes, eosinophilic esophagitis, atopic dermatitis, Current Opinion in Allergy and Clinical Churg-Strauss syndrome, and nasal polyposis. Immunology 2011, 11:565–570 Recent findings Recent trials of anti-IL-5 in patients with severe asthma refractory to existing therapies and prominent sputum eosinophilia experienced significant reductions in asthma exacerbations. Studies in patients with hypereosinopihilic syndromes have shown that IL-5 antagonism allows significant reductions in systemic corticosteroid doses while maintaining or improving blood eosinophil counts and symptoms. In children and adults with eosinophilic esophagitis, anti-IL-5 treatment reduced eosinophil numbers in esophageal tissue; it is uncertain whether these findings are predictive of clinical improvement. Clinical studies of individuals with atopic dermatitis do not support efficacy of anti-IL-5 in either reducing allergen patch test intensity or symptoms of chronic http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in Allergy and Clinical Immunology Wolters Kluwer Health

Anti-interleukin-5 antibody therapy in asthma and allerges

Loading next page...
 
/lp/wolters-kluwer-health/anti-interleukin-5-antibody-therapy-in-asthma-and-allerges-HrmEnfh9F2

References (36)

Copyright
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
ISSN
1528-4050
eISSN
1473-6322
DOI
10.1097/ACI.0b013e32834c3d30
pmid
21971335
Publisher site
See Article on Publisher Site

Abstract

Jonathan Corren Allergy Medical Clinic, Los Angeles, California, USA Purpose of review Interleukin 5 (IL-5) has been shown to play an instrumental role in eosinophilic Correspondence to Jonathan Corren, MD, Allergy Medical Clinic, 10780 Santa Monica Boulevard, inflammation in allergic diseases. The purpose of this review is to explore clinical trials of Suite 280, Los Angeles, CA 90025, USA anti-IL-5 antibody therapy that have been conducted in patients with asthma, Tel: +1 310 312 5050; e-mail: jcorren@ucla.edu hypereosinophilic syndromes, eosinophilic esophagitis, atopic dermatitis, Current Opinion in Allergy and Clinical Churg-Strauss syndrome, and nasal polyposis. Immunology 2011, 11:565–570 Recent findings Recent trials of anti-IL-5 in patients with severe asthma refractory to existing therapies and prominent sputum eosinophilia experienced significant reductions in asthma exacerbations. Studies in patients with hypereosinopihilic syndromes have shown that IL-5 antagonism allows significant reductions in systemic corticosteroid doses while maintaining or improving blood eosinophil counts and symptoms. In children and adults with eosinophilic esophagitis, anti-IL-5 treatment reduced eosinophil numbers in esophageal tissue; it is uncertain whether these findings are predictive of clinical improvement. Clinical studies of individuals with atopic dermatitis do not support efficacy of anti-IL-5 in either reducing allergen patch test intensity or symptoms of chronic

Journal

Current Opinion in Allergy and Clinical ImmunologyWolters Kluwer Health

Published: Dec 1, 2011

There are no references for this article.